Navigation Links
Adnexus Therapeutics Announces Presentation at the American,Association for Cancer Research (AACR) on Clinical Product,Candidate, CT-322

WALTHAM, Mass.--(BUSINESS WIRE)--Apr 17, 2007 - Adnexus(TM) Therapeutics, Inc. today announced the presentation of the abstract "CT-322: A specific VEGFR-2-blocking protein therapeutic agent with activity in preclinical tumor models comparable to pan-specific tyrosine kinase receptor inhibitors sunitinib and sorafenib" at the American Association for Cancer Research (AACR) 2007 annual meeting in Los Angeles, CA. The lead author is Irvith Carvajal, Ph.D., with Eric Furfine, Ph.D., senior vice president of research and preclinical development at Adnexus, presenting at the meeting.

CT-322 is a mono-specific blocker of the tyrosine kinase receptor, VEGFR-2, and blocks its activation by all known extracellular ligands; VEGF-A, VEGF-C, and VEGF-D. VEGFR-2 activation is the primary driver of tumor angiogenesis. In preclinical tumor models, CT-322 was compared to two approved pan-kinase inhibitors sunitinib and sorafenib. CT-322, sunitinib, and sorafenib each demonstrated comparable tumor growth suppression; however, CT-322 was better tolerated in the animal models.

"Our results suggest that 'pan-specific' kinase inhibitors may not offer improvement in anti-angiogenic induced tumor suppression over an extracellular, mono-specific blocker of VEGFR-2," commented Dr. Furfine. "CT-322's high affinity and selectivity for VEGFR-2 achieved comparable anti-tumor effect to molecules that inhibit a broad range of kinases."

"As cancer therapy evolves, the importance of efficacy, safety and tolerability of anti-angiogenic agents are becoming more pronounced due to the desire for combination therapy as well as longer duration of anti-angiogenic therapy," commented John Mendlein, Ph.D., chief executive officer of Adnexus. "We continue to extend our understanding of the VEGFR-2 pathway in tumor settings and its activation by VEGF-A, C and D. We are very encouraged by the emerging CT-322 Phase 1 data, and we look forward
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
5. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
6. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
7. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
8. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
9. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
10. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
11. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
Post Your Comments:
(Date:8/21/2014)... PARK, N.J. , Aug. 21, 2014 /PRNewswire/ ... pharmacy group purchasing organization (GPO), is pleased to ... to collaborate on a host of innovative specialty ... help Aurora deliver enhanced therapy management services to ... Management (OTM) system. Aurora will use ...
(Date:8/21/2014)... , Aug. 21, 2014 CVS Caremark Corporation (NYSE: ... applicable Reference Yields and consideration payable in connection with its ... August 7, 2014 for (1) any and all of its ... and (2) up to a maximum amount of its 6.125% ... 5.750% Senior Notes due 2017 (collectively, the "Maximum Tender Offer ...
(Date:8/21/2014)... -- Professional Compounding Centers of America (PCCA) will ... three best scientific presentations at the sixth ... Formulating Better Medicines for Children  conference, held ... Greece , includes dozens of poster-style scientific ... three winners will be selected by a panel ...
Breaking Medicine Technology:Aurora Health Care Partners with Armada Health Care to Deliver Added Pharmacy Capabilities to Specialty Patients 2Aurora Health Care Partners with Armada Health Care to Deliver Added Pharmacy Capabilities to Specialty Patients 3CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 2CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 3CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 4CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 5CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 6Professional Compounding Centers of America will award top poster-session winners at European Paediatric Formulation Initiative in Athens 2
... Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX ), ... human disease, announced today that Arthur T. Sands, ... will present at the Stifel Nicolaus Healthcare Conference in ... Eastern Time.  Dr. Sands will provide an overview on ...
... 2011 Reportlinker.com announces that a new market ... Pharmaceutical Distributors - Global ... This register contains information about 2800 ... register includes the following information about the ...
Cached Medicine Technology:Lexicon Pharmaceuticals to Present at Stifel Nicolaus Healthcare Conference 2
(Date:8/21/2014)... effective vaccination, polio is considered nearly eradicated. Each year ... scientists of the University of Bonn, together with colleagues ... that was able to resist the vaccine protection to ... outbreak in the Congo in 2010. The pathogen could ... results appear now in the magazine PNAS . ...
(Date:8/21/2014)... Irvine, CA (PRWEB) August 21, 2014 ... co-founder of American Corporate Health, was recently ... most influential professionals in the field of ... the National Workers’ Compensation and Occupational Medicine ... practitioners, including attorneys, physicians, nurses, case managers, ...
(Date:8/21/2014)... NY (PRWEB) August 21, 2014 Hospital ... a “topping off” ceremony for the new building at ... construction phase of the $125 million expansion and modernization ... a major donation from George S. Kaufman, Chairman of ... area to the Ambulatory Care Pavilion will be named. ...
(Date:8/21/2014)... to a new market report published by Transparency Market ... Share, Growth, Trends and Forecast, 2012 - 2018," the ... million in 2011 and is estimated to reach a ... CAGR of 6.3% from 2012 to 2018. , Browse ... , Fundus cameras market growth in recent years has ...
(Date:8/21/2014)... 2014 The new program, WellnessConnect ... Companies and builds on Accountable Health Solutions’ DiabetesConnect? ... combined with Accountable Health’s robust member engagement capabilities, ... and adds a custom incentive platform to help ... provider visits, HbA1c testing and more. ...
Breaking Medicine News(10 mins):Health News:Polio: Mutated virus breaches vaccine protection 2Health News:Dr. Vasili Gatsinaris Named One of the Top 50 Most Influential in Workers’ Compensation 2Health News:“Topping Off” Ceremony Marks Major Milestone in Mount Sinai Queens Construction Project 2Health News:“Topping Off” Ceremony Marks Major Milestone in Mount Sinai Queens Construction Project 3Health News:“Topping Off” Ceremony Marks Major Milestone in Mount Sinai Queens Construction Project 4Health News:Fundus Cameras Market: Product Type- Mydriatic, Non-Mydriatic, Hybrid and ROP Cameras; End Users- Hospitals, Ophthalmology Clinics and Ophthalmic & Optometrist Offices 2Health News:Accountable Health Expands Diabetes Management Solutions to Address Gaps in Provider Care 2Health News:Accountable Health Expands Diabetes Management Solutions to Address Gaps in Provider Care 3
... VANCOUVER, March 17 /PRNewswire-FirstCall/ - QLT Inc. ... Food and Drug Administration (FDA),has completed its review ... and has removed the glucose-6-phosphate dehydrogenase (G6PD),screening and ... to report the FDA decision to change the,Aczone ...
... Program Shows the Need Is Still There, WASHINGTON, ... who are still suffering emotionally from the,effects of the ... The American Red Cross Hurricane Recovery Program (HRP) has,announced ... Program until May 31, 2008. The Red Cross Emotional ...
... Hologic, Inc.,(Nasdaq: HOLX ) today announced that Patrick ... be presenting at the Lehman,Brothers Eleventh Annual Global Healthcare ... Hotel in Miami, Florida., Interested parties are invited ... presentation on Thursday, March 20, at 10:15 a.m.,Eastern Time ...
... The U.S. Pharmacopeial (USP) Convention today announced a ... (USP), an official compendium of the United States. ... and potentially fatal health hazards associated with diethylene ... in formulations of many pharmaceutical syrups and in ...
... staff can now be on the same page with ... Gua Para el Paciente Sobre Procedimientos de la Medicina ... both English and Spanish, the book explains in simple ... can expect prior to and during more than 30 ...
... (NYSE: BMY ) will present at the ... Brian Daniels, M.D., senior vice president,Global Development, will ... p.m. ET today., Bristol-Myers Squibb will also ... Wednesday, March 19, 2008. John Celentano, senior,vice president, ...
Cached Medicine News:Health News:QLT announces positive FDA action on Aczone(TM) 2Health News:QLT announces positive FDA action on Aczone(TM) 3Health News:Red Cross Announces an Extension for Emotional Support Assistance for 2005 Hurricane Survivors 2Health News:Hologic to Present at Lehman Brothers Healthcare Conference 2Health News:USP announces revised glycerin monograph 2Health News:Flip-chart book translates complicated medical procedures into easy-to-understand language 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: